Media and briefings
Prescient Therapeutics to present PTX-100 results at 5th World Congress of Cutaneous Lymphomas
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) will present results of its Phase 1b study of PTX-100 in T-cell lymphomas during a poster presentation ...
Read More
Read More
Prescient Therapeutics to present PTX-100 results at 5th World Congress of Cutaneous Lymphomas
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) will present results of its Phase 1b study of PTX-100 in T-cell lymphomas during a poster presentation ...
Read More
Read More
Prescient Therapeutics on cusp of value creation, says Pitt Street Research
In valuing Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) at A11.6 cents per share in its base case and A16.3 cents in its bull ...
Read More
Read More
Prescient Therapeutics (ASX: PTX) advances PTX-100 to pivotal Phase 2 study
PTX-100 of Prescient Therapeutics Limited (ASX: PTX) is in spotlight as it is entering a new stage. The company highlighted ...
Read More
Read More
Prescient Therapeutics secures speculative buy recommendation from Bioshares
Bioshares has a Speculative Buy Class B recommendation for Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) after the company released positive trial results from ...
Read More
Read More
STAY UP TO DATE
Register your details to receive company updates from Prescient Therapeutics
WEBCAST AND MEDIA
Prescient Therapeutics: Cell Therapies presentations from ISCT - 8th June 2023
Prescient Therapeutics: PTX-100 targeted cell therapy briefing - 2nd March 2023
Prescient Therapeutics CellPryme-A Briefing - 27 September 2022
Prescient Therapeutics (ASX:PTX) Investor Webcast - 10 June 2022
Prescient Therapeutics (ASX:PTX) Investor Webcast - 3 March 2022
Prescient Therapeutics (ASX:PTX) Investor Webcast - 19 October 2021
Prescient Therapeutics & Peter MacCallum Collaboration Update
Prescient Therapeutics with Special Guest Professor Miles Prince
Steven Yatomi Clarke on Stocks Down Under
ARTICLES
Follow us and stay connected
